Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Off-the-shelf mosunetuzumab/polatuzumab vedotin produced durable responses with manageable safety in BTK inhibitor–exposed relapsed/refractory MCL.

Fixed-Duration Mosunetuzumab/Polatuzumab Active in R/R MCL

Zidesamtinib, a brain-penetrant, TRK-sparing ROS1 TKI, showed activity and manageable safety in pretreated patients with advanced ROS1+ NSCLC.

Zidesamtinib Active, Safe in Pretreated ROS1+ Advanced NSCLC

Mosunetuzumab plus polatuzumab vedotin increased PFS and response rates vs R-GemOx in transplant-ineligible large B-cell lymphoma.

Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL

At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities from novel lymphoma therapies.

Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Events

Subscribe

Partners

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

Articles

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

FDA Approves Imlunestrant in ESR1+ HR+, HER2- Metastatic Breast Cancer

Caleb Raine, PA-C, is a physician assistant at Emory Winship Cancer Institute in Atlanta, Georgia.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

How Do BCMA-Targeting Bispecific Antibodies Work?

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Revumenib was added to NCCN guidelines for relapsed or refractory NPM1-mutated acute myeloid leukemia.

NCCN Recommends Revumenib for R/R NPM1+ Acute Myeloid Leukemia

Scott C. Borinstein, MD, PhD, is the medical director of Pediatric Hematology/Oncology at Vanderbilt Medical Center in Nashville, Tennessee.

Scott C. Borinstein, MD, PhD, discusses how holistic and empathetic care defines pediatric oncology.

Holistic, Compassionate Care Central to Pediatric Oncology

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

From All Angles 

Panelists emphasize a comprehensive, patient-centered approach to multiple myeloma care that integrates multidisciplinary expertise, personalized education, collaborative decision-making, innovative treatments, and strong support systems to improve outcomes and quality of life for patients and caregivers.

Patient Perspectives and Shared Decision-Making in Multiple Myeloma

From All Angles

Latest Conference Coverage